Dr.  Partha Ray, PhD - UCSD - Assistant Professor

Dr. Partha Ray

PhD

UCSD

Assistant Professor

San Diego , CA | United States

Main Specialties: Biology, Biotechnology

Additional Specialties: Aptamer Therapeutics

ORCID logohttps://orcid.org/0000-0002-7075-5463


Top Author

Dr.  Partha Ray, PhD - UCSD - Assistant Professor

Dr. Partha Ray

PhD

Introduction

I obtained my Ph.D. from Albert Einstein College of Medicine, Yeshiva University, New York. For my doctoral thesis, I applied various biochemical and genetic methods to study the interaction of nucleic acid and protein that is involved in the complex process of eukaryotic ribosome biogenesis. I combined my knowledge in Chemistry that I obtained through my Bachelor’s degree, and my doctoral training as a Biochemist, in a Clinical and Translational setting for my post-doctoral research at the Duke University Medical Center. I applied the Aptamer technology for the discovery and detection of novel biomarkers and as a platform for targeted drug delivery into cancer cells. Aptamers are short, single-stranded synthetic oligonucleotides that are capable of binding protein targets with high affinity and specificity, analogous to monoclonal antibodies. The research works have resulted in several high impact peer-reviewed publications and awards from international Oligonucleotide Therapeutics Society meetings. We were awarded a National Cancer Institute R21 grant to perform research on the application of aptamers as tools for biomarker discovery. I joined the Surgery Department of University of California, San Diego, as Assistant Professor in 2017 to establish my independent research group. My laboratory is located at the National Cancer Institute-designated Moores Cancer Center, UCSD, where I routinely collaborate with clinical-oncologists. My goal is to establish a team of basic-scientists, clinicians and bioengineers to find novel solutions for tumor-imaging and develop point-of-care devices to detect and monitor cancer biomarkers, by using the aptamer technology platform.


Primary Affiliation: UCSD - San Diego , CA , United States

Specialties:

Additional Specialties:

Research Interests:


View Dr. Partha Ray’s Resume / CV

Education

Dec 2016
Duke University
Senior Research Associate
Dec 2013
Duke University
Post Doctoral Associate
Jul 2002 - Sep 2008
Yeshiva University Albert Einstein College of Medicine
PhD
Developmental and Molecular Biology
Jun 2004
Albert Einstein College of Medicine
MS
Developmental and Molecular Biology
Jun 2001
University of Calcutta
M.Sc
Biochemistry
Jun 1999
University of Calcutta
B.Sc.
Chemistry (Honors)

Experience

Jan 2017 - Jan 2017
University of California, San Diego
Assistant Professor
Surgery
Jan 2017
Journal of Cancer Research and Therapeutic Oncology
Editor
Editorial Board Member
Dec 2008 - Dec 2016
Duke University
Research Associate, Senior
Surgery

Publications

14Publications

408Reads

17Profile Views

61PubMed Central Citations

Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor.

Mol Cancer Ther 2020 May 3;19(5):1173-1182. Epub 2020 Mar 3.

Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California, San Diego, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0959DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202956PMC
May 2020
5.683 Impact Factor

Comparison of gemcitabine delivery and tumor response in a pressurized pancreatic retrograde venous infusion versus systemic infusion in an orthotopic murine model.

Journal of Clinical Oncology

Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with limited response to systemic therapy (ST). Elevated tumor interstitial fluid pressures (IFP) inhibit penetration of ST. Regional Pressure Enabled Drug Delivery has recently demonstrated improved response for liver tumors in a clinical trial. However, this delivery method has not been evaluated in PDAC. We compared gemcitabine (Gem) by systemic delivery vs. a novel pressurized Pancreatic Retrograde Venous Infusion (PRVI) method in an orthotopic PDAC mouse model. Methods: PDAC murine cell line (KPC4580P) tumors were transplanted onto the pancreatic tail of C57BL/6J mice. Groups of 15 mice were randomly assigned to PRVI Gem, PRVI saline (Control), or intraperitoneal Gem (Systemic) groups. Five mice from the PRVI and Systemic groups were randomly selected after one hour post infusion to evaluate Gem tumor concentrations by liquid chromatography - tandem mass spectrometry (ng/mg), and the remainder of mice were euthanized after 7 days to evaluate treatment response. Results: Tumor concentrations of Gem were significantly higher following PRVI compared to Systemic (128 vs. 19, p < 0.01) at one hour after treatment. Seven days after treatment, PRVI Gem mice demonstrated lower mean tumor volume (mm3) than Systemic Gem and Control mice (274 vs. 857 vs. 629, p < 0.01), respectively. Histologic evaluation of tumors demonstrated decreased cellularity in the PRVI Gem mice compared to Systemic and Control mice (35 vs. 78 vs. 71%, p = 0.01), respectively. No differences were seen in Ki67% or immune cell infiltrate between groups. Conclusions: PRVI delivery resulted in increased PDAC Gem concentrations and improved treatment responses with decreased tumor burden and cellularity. These findings suggest that pressurized regional chemotherapy infusion overcomes the elevated PDAC IFP and justifies additional translational pre-clinical studies with other chemotherapeutics (including immunomodulating antibodies) with different physicochemical properties.

View Article
February 2020
6 Reads

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation.

J Vis Exp 2018 06 8(136). Epub 2018 Jun 8.

Moores Cancer Center, University California San Diego;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/57265DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101643PMC
June 2018
40 Reads

Cell-SELEX Identifies a “Sticky” RNA Aptamer

Volume 2017 (2017), Article ID 4943072, 9 pages

Journal of Nucleic Acids

Cell-SELEX is performed to select for cell binding aptamers. We employed an additional selection pressure by using RNAse to remove surface-binding aptamers and select for cell-internalizing aptamers. A common RNA sequence was identified from independent cell-SELEX procedures against two different pancreatic cancer cell lines, indicating a strong selection pressure towards this sequence from the large pool of other available sequences present in the aptamer library. The aptamer is not specific for the pancreatic cancer cell lines, and a similar sequence motif is present in previously published internalizing aptamers. The identified sequence forms a structural motif that binds to a surface protein, which either is highly abundant or has strong affinity for the selected aptamer sequence. Deselecting (removing) this sequence during cell-SELEX may increase the probability of identifying aptamers against cell type-specific targets on the cell surface.

View Article
January 2017
62 Reads

In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9.

Mol Ther Nucleic Acids 2016 Apr 26;5:e315. Epub 2016 Apr 26.

Department of Surgery, University of California at San Diego, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/mtna.2016.27DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014527PMC
April 2016
52 Reads
7 Citations

Utilizing RNA aptamers for Biomarker Discovery in a Novel Cell Culture System for Hepatocellular Carcinoma

Journal of Surgical Research. 02/2014; 186(2):680. DOI: 10.1016/j.jss.2013.11.904

Journal of Surgical Research

View Article
February 2014
18 Reads

Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.

Nucleic Acid Ther 2013 Dec 23;23(6):435-42. Epub 2013 Oct 23.

Department of Surgery, Duke University School of Medicine , Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/nat.2013.0439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868381PMC
December 2013
39 Reads
2 Citations
2.890 Impact Factor

Application of aptamers for targeted therapeutics.

Arch Immunol Ther Exp (Warsz) 2013 Aug 7;61(4):255-71. Epub 2013 Apr 7.

Department of Surgery, Duke University Medical Center, DUMC Box 103035, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00005-013-0227-0DOI Listing
August 2013
34 Reads
10 Citations
3.180 Impact Factor

Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.

Nucleic Acid Ther 2012 Oct;22(5):295-305

Department of Surgery, Duke University School of Medicine, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/nat.2012.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464421PMC
October 2012
30 Reads
13 Citations
2.890 Impact Factor

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker.

J Clin Invest 2012 May 9;122(5):1734-41. Epub 2012 Apr 9.

Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI62385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336995PMC
May 2012
23 Reads
13 Citations
13.215 Impact Factor

The Saccharomyces cerevisiae 60 S ribosome biogenesis factor Tif6p is regulated by Hrr25p-mediated phosphorylation.

J Biol Chem 2008 Apr 5;283(15):9681-91. Epub 2008 Feb 5.

Department of Developmental and Molecular Biology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M710294200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442299PMC
April 2008
34 Reads
16 Citations
4.573 Impact Factor

Activation of S phase checkpoint by cigarette smoke extract in Schizosaccharomyces pombe.

Yeast 2005 Nov;22(15):1223-38

Dr B.C. Guha Centre for Genetic Engineering and Biotechnology, Department of Biochemistry, University of Calcutta, 35 B.C. Road, Kolkata 700019, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/yea.1309DOI Listing
November 2005
52 Reads
1.634 Impact Factor

Top co-authors

Rebekah R White
Rebekah R White

Duke University Medical Center

6
Bruce A Sullenger
Bruce A Sullenger

Duke University Medical Center

4
Andrew D Ellington
Andrew D Ellington

Institute for Cellular and Molecular Biology

1
Barbara Ramsay Shaw
Barbara Ramsay Shaw

Duke University

1
Na Li
Na Li

School of Environmental Science and Engineering

1
Mariam L Sharaf
Mariam L Sharaf

Infectious Disease Interdisciplinary Research Group

1
Marcus A Cheek
Marcus A Cheek

Department of Chemistry

1
Emanuela Veras
Emanuela Veras

The University of Texas Medical School at Houston

1
Erin E Soule
Erin E Soule

Royal College of Surgeons in Ireland

1